Fixing Faulty Lysosomes Rejuvenates Aged Blood Stem Cells by Eightfold
Scientists reversed aging in blood stem cells by targeting hyperactive lysosomes, boosting repopulation capacity over eightfold and restoring youthful function.
Summary
Researchers at Mount Sinai discovered that lysosomes — the cell's recycling centers — become hyperacidic, damaged, and overactive in aged hematopoietic stem cells (HSCs). This dysfunction drives inflammation, epigenetic disruption, and impaired blood cell production in old age. By treating aged HSCs with a vacuolar ATPase (v-ATPase) inhibitor to suppress lysosomal hyperactivation, the team restored lysosomal integrity, metabolic balance, and epigenetic homeostasis. The intervention also reduced inflammatory and interferon signaling by improving clearance of mitochondrial DNA. Remarkably, a brief ex vivo treatment increased aged HSCs' ability to repopulate blood systems in vivo by more than eightfold, offering a compelling new strategy to combat age-related blood disorders and immune decline.
Detailed Summary
As we age, our blood and immune systems deteriorate partly because hematopoietic stem cells (HSCs) — the master cells that generate all blood cell types — lose their regenerative capacity. This decline contributes to clonal hematopoiesis, myeloid malignancies, and weakened immunity. Understanding what drives HSC aging at a molecular level is critical to developing interventions that restore healthy blood production in elderly individuals.
Researchers from the Icahn School of Medicine at Mount Sinai focused on lysosomes, organelles traditionally viewed as passive recycling compartments. They found that in aged HSCs, lysosomes are not simply declining — they are hyperacidic, depleted in number, physically damaged, and aberrantly overactivated. This represents a gain-of-dysfunction phenotype rather than mere wear-and-tear.
Using single-cell transcriptomics alongside functional assays, the team showed that pharmacological suppression of lysosomal hyperactivation with a vacuolar ATPase (v-ATPase) inhibitor normalized lysosomal pH and structure, restored metabolic homeostasis, and re-established epigenetic balance in old HSCs. A key mechanism identified was improved lysosomal processing of mitochondrial DNA, which reduced activation of the cGAS-STING innate immune pathway — a major driver of chronic inflammation and interferon signaling in aging tissues.
The functional results were striking: ex vivo treatment of aged HSCs with the v-ATPase inhibitor enhanced their in vivo blood repopulation capacity by over eightfold and improved self-renewal — hallmarks of a youthful HSC state. These findings elevate lysosomal dysfunction from a secondary consequence of aging to a primary causal driver.
While the study is predominantly preclinical and based on mouse models, it identifies a targetable mechanism with clear translational potential. V-ATPase inhibitors and related lysosome-modulating agents could eventually be developed as therapies to rejuvenate HSC function in older patients, particularly those at risk of blood cancers or immune failure.
Key Findings
- Aged HSCs harbor hyperacidic, damaged, and overactivated lysosomes — a gain-of-dysfunction rather than simple decline.
- V-ATPase inhibition restores lysosomal integrity, metabolic balance, and epigenetic homeostasis in old HSCs.
- Lysosomal dysfunction drives chronic inflammation via impaired mitochondrial DNA clearance and cGAS-STING activation.
- Ex vivo lysosomal inhibition boosts aged HSC in vivo repopulation capacity by over eightfold.
- Lysosomal hyperactivation is identified as a key causal driver of HSC aging, not merely a downstream consequence.
Methodology
The study combined single-cell transcriptomics with functional stem cell assays to characterize lysosomal states in young versus aged mouse HSCs. Pharmacological inhibition of v-ATPase was applied ex vivo, with outcomes assessed through in vivo bone marrow repopulation experiments. Multi-omics approaches captured metabolic, epigenetic, and inflammatory pathway changes.
Study Limitations
The study appears primarily based on mouse models, and translation to human HSC biology requires validation. The abstract does not detail long-term safety of v-ATPase inhibition or potential off-target effects on other stem cell populations. Access to the full paper is restricted, limiting evaluation of experimental depth and controls.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: